DrugPatentWatch Database Preview
Drugs in Development Information for Motesanib
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for Motesanib?
Motesanib is an investigational drug.
There have been 13 clinical trials for Motesanib.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2012.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Breast Neoplasms. The leading clinical trial sponsors are Amgen, National Cancer Institute (NCI), and Takeda.
Summary for Motesanib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 250 |
| WIPO Patent Applications | 191 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2012-07-01) |
| Vendors | 68 |
Recent Clinical Trials for Motesanib
| Title | Sponsor | Phase |
|---|---|---|
| Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | Amgen | Phase 1/Phase 2 |
| Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | Susan G. Komen Breast Cancer Foundation | Phase 1/Phase 2 |
| Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | Sidney Kimmel Cancer Center at Thomas Jefferson University | Phase 1/Phase 2 |
Clinical Trial Summary for Motesanib
Top disease conditions for Motesanib
Top clinical trial sponsors for Motesanib
US Patents for Motesanib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
